创新的基于病理网络的多目标方法用于阿尔茨海默氏症治疗
Paloma Mayo1,2,3, Jorge Pascual1,3, Enrique Crisman3
1Departamento de desarrollo preclínico, Fundación Teófilo Hernando, Las Rozas, Madrid, Spain.
Medicinal research reviews
|April 28, 2024
概括
阿尔茨海默病 (AD) 是一个日益增长的全球健康威胁. 本综述探讨了多目标药物开发策略,旨在通过同时针对多个途径来解决AD复杂的病理问题.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是最常见的神经退行性疾病,构成了全球健康的重大挑战.
- 由于人口老龄化,预计阿尔茨海默病的患病率将在未来几十年内急剧上升.
- 目前的AD治疗只能提供症状缓解,不能阻止疾病的进展.
研究的目的:
- 审查在过去十年中针对阿尔茨海默病的多目标药物开发的进展.
- 突出使用多目标导向连接体的战略,以解决AD的复杂,多因素性质.
- 讨论如何针对多个病理节点可能提供更有效的治疗方法.
主要方法:
- 科学出版物和药物开发管道的文献综述.
- 分析多目标药物策略及其基础的药理学原则.
- 检查新病理途径发现对阿尔茨海默病的药物化学的影响.
主要成果:
- 多向药物的开发在阿尔茨海默病研究中获得了推动力.
- 这些药物旨在与复杂的AD病理网络中的多个目标相互作用.
- 该审查侧重于过去十年中药物化学和药物设计方面的进展.
结论:
- 多目标药物开发是对抗阿尔茨海默病的有希望的战略.
- 通过参与多种病理途径,这些药物旨在延迟或阻止疾病的进展.
- 对阿尔茨海默症病理的复杂相互作用的持续研究对于推进治疗选择至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468